Rett syndrome: Clinical review and genetic update

Journal of Medical Genetics

Volumn 42, Issue 1, 2005, Pages 1-7

  Weaving, L S ^b   Ellaway, C J ^a,c   Gecz J ^d,e   Christodoulou, J ^a,c,d  

^a CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

^c UNIVERSITY OF SYDNEY   (Australia)

^d WOMEN S AND CHILDREN S HOSPITAL   (Australia)

^e UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANESTHETIC AGENT; ANTIARRHYTHMIC AGENT; ANTIBIOTIC AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; CARNITINE; CISAPRIDE; CYCLIN DEPENDENT KINASE LIKE 5; ERYTHROMYCIN; IMIPRAMINE; KETOCONAZOLE; MESSENGER RNA; METHYL CPG BINDING PROTEIN 2; NEUROLEPTIC AGENT; PROKINETIC AGENT; PROTEIN SERINE THREONINE KINASE; QUINIDINE; SERINE THREONINE KINASE 9; SOTALOL; SUXAMETHONIUM; THIOPENTAL; THIORIDAZINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG;

ANIMAL CELL; BDNF GENE; BRACE; BREATHING DISORDER; CDKL5 GENE; CENTRAL NERVOUS SYSTEM; DEVELOPMENTAL DISORDER; DISABILITY; ELECTROCARDIOGRAM; ELECTROENCEPHALOGRAM; FEEDING DISORDER; FEMALE; GASTROESOPHAGEAL REFLUX; GENE; GENE EXPRESSION; GENE MUTATION; GENE STRUCTURE; HAIRY2A GENE; HEART ARRHYTHMIA; HUMAN; MECP2 GENE; MENTAL DEFICIENCY; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; QT PROLONGATION; RAT; RETT SYNDROME; REVIEW; SCOLIOSIS; SEIZURE; SYNDROME DELINEATION; X CHROMOSOME INACTIVATION;

ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; METHYL-CPG-BINDING PROTEIN 2; MUTATION; NEURONS; PROTEIN-SERINE-THREONINE KINASES; RETT SYNDROME;

ANIMALIA;

EID: 13244262974     PISSN: 00222593     EISSN: None     Source Type: Journal    
DOI: 10.1136/jmg.2004.027730     Document Type: Review

References (103)

1. Rett A. Uber ein eigartiges hirnatrophisches Syndrom bei Hyperammoniamie in Kindesalter. Wien Med Wochenschr 1966;116:723-38.
2. Hagberg B, Aicardi J, Dias K, Ramos O. Progressive syndrome of autism, dementia, ataxia and loss of purposeful hand use in girls: Rett's syndrome: Report of 35 cases. Ann Neurol 1983;14:471-9.
3. Hagberg B, Hagberg G. Rett syndrome: epidemiology and geographical variability. Eur Child Adolesc Psych 1997;1:5-7.
4. Leonard H, Bower C, English D. The prevalence and incidence of Rett syndrome in Australia. Eur Child Adolesc Psych 1997;1:8-10.
5. Hagberg B. Rett syndrome: clinical peculiarities and biological mysteries. Acta Paediatr 1995;84:971-6.
6. Amir RE, Van den Veyver IB, Wan M, Tran CQ, Francke U, Zoghbi HY. Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat Genet 1999;23185-8.
7. Trevethan E, Moser H, for the Rett Syndrome Diagnostic Working Group. Diagnostic criteria for Rett syndrome. Ann Neurol 1988;23:425-8.
8. Hagberg B, Hanefeld F, Percy A, Skjeldal O. An update on clinically applicable diagnostic criteria in Rett syndrome. Comments to Rett Syndrome Clinical Criteria Consensus Panel Satellite to European Paediatric Neurology Society Meeting, Baden Baden, Germany, 11 September 2001. Eur J Paediatr Neurol 2002;6:293-7.
9. Kerr AM, Nomura Y, Armstrong D, Anvret M, Belichenko PV, Budden S, Cass H, Christodoulou J, Clarke A, Ellaway C, d'Esposito M, Francke U, Hulten M, Julu P, Leonard H, Naidu S, Schanen C, Webb T, Engerstrom IW, Yamashita Y, Segawa M. Guidelines for reporting clinical features in cases with MECP2 mutations. Brain Dev 2001;23:208-11.
10. Hagberg B, Witt-Engerstrom I. Rett syndrome: a suggested staging system for describing impairment profile with increasing age towards adolescence. Am J Med Genet 1986;24(suppl):47-59.
11. Ellaway CS, Badawi N, Raffaele L, Christodoulou J, Leonard H. A case of multiple congenital anomalies in association with Rett syndrome confirmed by MECP2 mutation screening. Clin Dysmorph 2001;10:185-8.
12. Leonard H, Weaving L, Eastaugh P, Smith L, Delatycki M, Witt Engerstrom I, Christodoulou J. Trisomy 21 and Rett syndrome: a double burden. J Paediatr Child Health 2004;40:406-9.
13. Hagberg B, Gillberg C. Rett variants-rettoid phenotypes. In: Hagberg B, Anvret M, Wahlstrom J, eds. Rett syndrome-clinical and biological aspects. London: MacKeith Press, 1993:40-60.
14. Schwartzman JS, Bernardino A, Nishimura A, Gomes RR, Zatz M. Rett syndrome in a boy with a 47,XXY karyotype confirmed by a rare mutation in the MECP2 gene. Neuropediatr 2001;32:162-4.
15. Topcu M, Akyerli C, Sayi A, Toruner GA, Kocoglu SR, Cimbis M, Ozcelik T. Somatic mosaicism for a MECP2 mutation associated with classic Rett syndrome in a boy. Fur J Hum Genet 2002;10:77-81.
16. Moog U, Smeets EE, van Roozendaal KE, Schoenmakers S, Herbergs J, Schoonbrood-Lenssen AM, Schrander-Stumpel CT. Neurodevelopmental disorders in males related to the gene causing Rett syndrome in females (MECP2). Eur J Paediatr Neurol 2003;7:5-12.
17. Plioplys AV, Kasnicka I. L-carnitine as a treatment for Rett syndrome. South Med J 1993;86:1411-12.
18. Ellaway C, Williams K, Leonard H, Higgins G, Wilcken B, Christodoulou J. Rett syndrome: randomized controlled trial of L-carnitine. J Child Neurol 1999;14:162-7.
19. Ellaway CJ, Peat J, Williams K, Leonard H, Christodoulou J. Medium-term open label trial of L-carnitine in Rett syndrome. Brain Dev 2001;23(suppl 1):S85-9.
20. Egger J, Hofacker N, Schiel W, Holthausen H. Magnesium for hyperventilation in Rett's syndrome. Lancet 1992;340:621-2.
21. McArthur AJ, Budden SS. Sleep dysfunction in Rett syndrome: a trial of exogenous melatonin treatment. Dev Med Child Neurol 1998;40:186-92.
22. Budden SS. Management of Rett syndrome: a ten year experience. Neuropediatr 1995;26:75-7.
23. Budden SS. Rett syndrome: habilitation and management reviewed. Eur Child Adol Psych 1997;1:103-7.
24. Glaze DG, Schultz RJ, Frost JD. Rett syndrome: characterization of seizures versus non-seizures. Electroencephal Clin Neurophysiol 1998;106:79-83.
25. Sekul EA, Moak JP, Schultz RJ, Glaze DG, Dunn JK, Percy AK. Electrocardiographic findings in Rett syndrome: an explanation for sudden death? J Pediatr 1994;125:80-82.
26. Ellaway CJ, Sholler G, Leonard H, Christodoulou J. Prolonged QT interval in Rett syndrome. Arch Dis Child 1999;80:470-2.
27. Hanks SB. Motor disabilities in the Rett syndrome and physical therapy strategies. Brain Dev 1990;12:157-61.
28. Adler DA, Quaderi NA, Brown SD, Chapman VM, Moore J, Tate P, Disteche CM. The X-linked methylated DNA binding protein, Mecp2, is subject to X inactivation in the mouse. Mamm Genome 1995;6:491-2.
29. D'Esposito M, Quaderi NA, Ciccodicola A, Bruni P, Esposito T, D'Urso M, Brown SD. Isolation, physical mapping, and northern analysis of the X-linked human gene encoding methyl CpG-binding protein, MECP2. Mamm Genome 1996;7:533-5.
30. Kriaucionis S, Bird A. The major form of MeCP2 has a novel N-terminus generated by alternative splicing. Nucl Acid Res 2004;32:1818-23.
31. Mnatzakanian GN, Lohi H, Munteanu I, Alfred SE, Yamada T, MacLeod PJ, Jones JR, Scherer SW, Schanen NC, Priez MJ, Vincent JB, Minassian BA. A previously unidentified MECP2 open reading frame defines a new protein isoform relevant to Rett syndrome. Nat Genet 2004;36339-41.
32. Jones PL, Veenstra GJ, Wade PA, Vermaak D, Kass SU, Landsberger N, Strouboulis J, Wolffe AP. Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat Genet 1998;19:187-91.
33. Nan X, Ng HH, Johnson CA, Laherty CD, Turner BM, Eisenman RN, Bird A. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature 1998;393:386-9.
34. Kokura K, Kaul SC, Wadhwa R, Nomura T, Khan MM, Shinagawa T, Yasukawa T, Colmenares C, Ishii S. The Ski protein family is required for MeCP2-mediated transcriptional repression. J Biol Chem 2001;276:34115-21.
35. Yu F, Thiesen J, Stratling WH. Histone deacetylase-independent transcriptional repression by methyl-CpG-binding protein 2. Nucl Acid Res 2000;28:2201-6.
36. Buschdorf JP, Stratling WH. A WW domain binding region in methyl-CpG-binding protein MeCP2: impact on Rett syndrome. J Mol Med 2004;82:135-43.
37. Amir RE, Van den Veyver IB, Schultz R, Malicki DM, Tran CQ, Dahle EJ, Philippi A, Timor L, Percy AK, Motil KJ, Lichtarge O, Smith EO, Glaze DG, Zoghbi HY. Influence of mutation type and X chromosome inactivation on Rett syndrome phenotypes. Ann Neurol 2000;47:670-9.
38. Hoffbuhr K, Devaney JM, LaFleur B, Sirianni N, Scacheri C, Giron J, Schuette J, Innis J, Marino M, Philippart M, Narayanan V, Umansky R, Kronn D, Hoffman EP, Naidu S. MeCP2 mutations in children with and without the phenotype of Rett syndrome. Neurol 2001;56:1486-95.
39. Laccone F, Huppke P, Hanefeld F, Meins M. Mutation spectrum in patients with Rett syndrome in the German population: Evidence of hot spot regions. Human Mut 2001;17:183-90.
40. Huppke P, Held M, Hanefeld F, Engel W, Laccone F. Influence of mutation type and location on phenotype in 123 patients with Rett syndrome. Neuropediatr 2002;33:63-8.
41. Weaving LS, Williamson SL, Bennetts B, Davis M, Ellaway CJ, Leonard H, Thong MK, Delatycki M, Thompson EM, Laing N, Christodoulou J. Effects of MECP2 mutation type, location and X-inactivation in modulating Rett syndrome phenotype. Am J Med Genet 2003;118A:103-14.
42. Kammoun F, de Roux N, Boespflug-Tanguy O, Vallee L, Seng R, Tardieu M, Landrieu P. Screening of MECP2 coding sequence in patients with phenotypes of decreasing likelihood for Rett syndrome: a cohort of 171 cases. J Med Genet 2004;41:e85.
43. Schanen C, Houwink EJ, Dorrani N, Lane J, Everett R, Feng A, Cantor RM, Percy A. Phenotypic manifestations of MECP2 mutations in classical and atypical Rett syndrome. Am J Med Genet 2004;126A:129-40.
44. Christodoulou J, Grimm A, Maher T, Bennetts B. RettBASE: The IRSA MECP2 variation database-a new mutation database in evolution. Hum Mut 2003;21:466-72.
45. Leonard H, Colvin L, Christodoulou J, Schiavello T, Williamson S, Davis M, Ravine D, Fyfe S, de Klerk N, Matsuishi T, Kondo I, Clarke A, Hackwell S, Yamashita Y. Patients with the R133C mutation: is their phenotype different from patients with Rett syndrome with other mutations? J Med Genet 2003;40:e52.
46. Colvin L, Leonard H, de Klerk N, Davis M, Weaving L, Williamson S, Christodoulou J. Refining the phenotype of common mutations in Rett syndrome. J Med Genet 2004;41:25-30.
47. Camus P, Abbadi N, Perrier MC, Chery M, Gilgenkrantz S. Patterns of X chromosome inactivation in the Rett syndrome. Brain Dev 1990;12:131-5.
48. Camus P, Abbadi N, Perrier MC, Chery M, Gilgenkrantz S. X chromosome inactivation in 30 girls with Rett syndrome: analysis using the probe. Hum Genet 1996;97:247-50.
49. Krepischi AC, Kok F, Otto PG. X chromosome-inactivation patterns in patients with Rett syndrome. Hum Genet 1998;102:319-21.
50. Webb T, Watkiss E, Woods CG. Neither uniparental disomy nor skewed X-inactivation explains Rett syndrome. Clin Genet 1993;44:236-40.
51. Anvret M, Wahlstrom J. Rett syndrome: random X chromosome inactivation. Clin Genet 1994;45:274-75.
52. Migeon BR, Dunn MA, Thomas G, Schmeckpeper BJ, Naidu S. Studies of X inactivation and isodisomy in twins provide further evidence that the X chromosome is not involved in Rett syndrome. Am J Hum Genet 1995;56:647-63.
53. Webb T, Watkiss E. A comparative study of X-inactivation in Rett syndrome probands and control subjects. Clin Genet 1996;49:189-15.
54. Hoffbuhr KC, Moses LM, Jerdonek MA, Naidu S, Hoffman EP. Associations between MeCP2 mutations, X-chromosome inactivation, and phenotype. Mental Retard Dev Disab Res Rev 2002;8:99-105.
55. Shahbazian MD, Sun Y, Zoghbi HY. Balanced X chromosome inactivation patterns in the Rett syndrome brain. Am J Med Genet 2002;111:164-8.
56. Balmer D, Arredondo J, Samaco RC, LaSalle JM. MECP2 mutations in Rett syndrome adversely affect lymphocyte growth, but do not affect imprinted gene expression in blood or brain. Hum Genet 2002;110:545-52.
57. Young JI, Zoghbi HY. X-chromosome inactivation patterns are unbalanced and affect the phenotypic outcome in a mouse model of Rett syndrome. Am J Hum Genet 2004;74:511-50.
58. Braunschweig D, Simcox T, Somaco RC, LaSalle JM. X-Chromosome inactivation ratios affect wild-type MeCP2 expression within mosaic Rett syndrome and Mecp2-/+ mouse brain. Hum Mol Genet 2004;13:1275-86.
59. Chen RZ, Akbarian S, Tudor M, Jaenisch R. Deficiency of methyl-CpG binding protein-2 in CNS neurons results in a Rett-like phenotype in mice. Nat Genet 2001;27:327-31.
60. Guy J, Hendrich B, Holmes M, Martin JE, Bird A. A mouse Mecp2-null mutation causes neurological symptoms that mimic Rett syndrome. Nat Genet 2001;27:322-6.
61. Gibson J, Williamson S, Arbuckle S, Christodoulou J. X chromosome inactivation patterns of the rain in Rett syndrome: implications for the disease phenotype. Brain Dev (in press).
62. Erlandson A, Samuelsson L, Hagberg B, Kyllerman M, Vujic M, Wahlstrom J. Multiplex ligation-dependent probe amplification (MLPA) detects large deletions in the MECP2 gene of Swedish Rett syndrome patients. Genet Test 2003;7:329-32.
63. Schollen E, Smeets E, Deflem E, Fryns JP, Matthijs G. Gross rearrangements in the MECP2 gene in three patients with Rett syndrome: implications for routine diagnosis of Rett syndrome. Hum Mut 2003;22:116-20.
64. Ariani F, Mari F, Pescucci C, Longo I, Bruttini M, Meloni I, Hayek G, Rocchi R, Zappella M, Renieri A. Real-time quantitative PCR as a routine method for screening large rearrangements in Rett syndrome: Report of one case of MECP2 deletion and one case of MECP2 duplication. Human Mut 2004;24:172-7.
65. Laccone F, Junemann I, Whatley S, Morgan R, Butler R, Huppke P, Ravine D. Large deletions of the MECP2 gene detected by gene dosage analysis in patients with Rett syndrome. Hum Mut 2004;23:234-44. Erratum appears in Hum Mut 2004;23:395.
66. Laccone F, Junemann I, Whatley S, Morgan R, Butler R, Huppke P, Ravine D. Large deletions of the MECP2 gene detected by gene dosage analysis in patients with Rett syndrome. Hum Mut 2004;23:234-44. Erratum appears in Hum Mut 2004;23:395.
67. Evans JC, Archer HL, Whatley SD, Kerr A, Clarke A, Butler R. Variation in exon 1 coding region and promoter of MECP2 in Rett syndrome and controls. Eur J Hum Genet 2004;(in press).
68. Coy JF, Sedlacek Z, Bachner D, Delius H, Poustka A. A complex pattern of evolutionary conservation and alternative polyadenylation within the long 3′-untranslated region of the methyl-CpG-binding protein 2 gene (MeCP2) suggests a regulatory role in gene expression. Hum Mol Genet 1999;8:1253-62.
69. Too J, Van Esch H, Hagedorn-Greiwe M, Hoffmann K, Moser B, Raynaud M, Sperner J, Fryns JP, Schwinger E, Gecz J, Ropers HH, Kalscheuer VM. De novo mutations in the X-linked serine/threonine kinase 9 (STK9) gene are associated with a severe variant of Rett syndrome. Am J Hum Genet 2004;75:Epub.
70. Weaving LS, Christodoulou J, Williamson SL, Friend KL, McKenzie OL, Archer H, Evans J, Clarke A, Pelka GJ, Tam PP, Watson C, Lahooti H, Ellaway O, Bennetts B, Leonard H, Gecz J. Mutations of CDKL5 cause a severe neurodevelopmental disorder with infantile spasms and mental retardation. Am J Hum Genet 2004;75:Epub.
71. Wan M, Lee SS, Zhang X, Houwink-Manville I, Song HR, Amir RE, Budden S, Naidu S, Pereira JL, La IF, Zoghbi HY, Schonen NC, Francke U. Rett syndrome and beyond: recurrent spontaneous and familial MECP2 mutations at CpG hotspots. Am J Hum Genet 1999;65:1520-9.
72. Miltenberger-Miltenyi G, Laccone F. Mutations and polymorphisms in the human methyl CpG-binding protein MECP2. Hum Mut 2003;22:107-15.
73. Kerr AM, Ravine D. Review article: breaking new ground with Rett syndrome. J Intellect Disab Res 2003;47:580-7.
74. Thomas GH. High male:female ratio of germ-line mutations: an alternative explanation for postulated gestational lethality in males in X-linked dominant disorders. Am J Hum Genet 1996;58:1364-8.
75. Girard M, Couvert P, Carrie A, Tardieu M, Chelly J, Beldjord C, Bienvenu T. Parental origin of de novo MECP2 mutations in Rett syndrome. Eur J Hum Genet 2001;9:231-6.
76. Trappe R, Laccone F, Cobilanschi J, Meins M, Huppke P, Hanefeld F, Engel W. MECP2 mutations in sporadic cases of Rett syndrome are almost exclusively of paternal origin. Am J Hum Genet 2001;68:1093-101.
77. Amir RE, Zoghbi HY. Rett syndrome: methyl-CpG-binding protein 2 mutations and phenotype-genotype correlations. Am J Med Genet 2000;97:147-52.
78. Meloni I, Bruttini M, Longo I, Mari F, Rizzolio F, D'Adamo P, Denvriendt K, Fryns JP, Toniolo D, Renieri A. A mutation in the Rett syndrome gene, MECP2, causes X-linked mental retardation and progressive spasticity in males. Am J Hum Genet 2000;67:982-5.
79. Orrico A, Lam C, Galli L, Dotti MT, Hayek G, Tong SF, Poon PM, Zappella M, Federico A, Sorrentino V. MECP2 mutation in male patients with non-specific X-linked mental retardation. FEBS Lett 2000;481:285-8.
80. Dotti MT, Orrico A, De Stefano N, Battisti C, Sicurelli F, Severi S, Lam CW, Galli L, Sorrentino V, Federico A. A Rett syndrome MECP2 mutation that causes mental retardation in men. Neurol 2002;58:226-30.
81. Kleefstra T, Yntema HG, Oudakker AR, Romein T, Sistermans E, Nillessen W, van Bokhoven H, de Vries BB, Hamel BC. De novo MECP2 frameshift mutation in a boy with moderate mental retardation, obesity and gynaecomastia. Clin Genet 2002;61:359-62.
82. Yntema HG, Kleefstra T, Oudakker AR, Romein T, de Vries BB, Nillesen W, Sistermans EA, Brunner HG, Hamel BC, van Bokhoven H. Low frequency of MECP2 mutations in mentally retarded males. Eur J Hum Genet 2002;10:487-90.
83. Klauck SM, Lindsay S, Beyer KS, Splitt M, Burn J, Poustka A. A mutation hot spot for nonspecific X-linked mental retardation in the MECP2 gene causes the PPM-X syndrome. Am J Hum Genet 2002;70:1034-7.
84. Watson P, Black G, Ramsden S, Barrow M, Super M, Kerr B, Clayton-Smith J. Angelman syndrome phenotype associated with mutations in MECP2, a gene encoding a methyl CpG binding protein. J Med Genet 2001;38:224-8.
85. Kleefstra T, Yntema HG, Nillesen WM, Oudakker AR, Mullaart RA, Geerdink N, van Bokhoven H, de Vries BB, Sistermans EA, Hamel BC. MECP2 analysis in mentally retarded patients: implications for routine DNA diagnostics. Eur J Hum Genet 2004;12:24-8.
86. Beyer KS, Blasi F, Bacchelli E, Klauck SM, Maestrini E, Poustka A, International Molecular Genetic Study of Autism Consortium (IMGSAC). Mutation analysis of the coding sequence of the MECP2 gene in infantile autism. Hum Genet 2002;111:305-9.
87. Traynor J, Agarwal P, Lazzeroni L, Francke U. Gene expression patterns vary in clonal cell cultures from Rett syndrome females with eight different MECP2 mutations. BMC Med Genet 2002;3:5.
88. Tudor M, Akbarian S, Chen RZ, Jaenisch R. Transcriptional profiling of a mouse model for Rett syndrome reveals subtle transcriptional changes in the brain. Proc Natl Acad Sci USA 2002;99:15536-41.
89. Colanhioni C, Jeon OH, Hyder K, Chenchik A, Khimani AH, Narayanan V, Hoffman EP, Kaufmann WE, Naidu S, Pevsner J. Gene expression profiling in postmortem Rett Syndrome brain: differential gene expression and patient classification. Neurobiol Dis 2001;8:847-65.
90. Stancheva I, Collins AL, Van den Veyver IB, Zoghbi H, Meehan RR. A mutant form of MeCP2 protein associated with human Rett syndrome cannot be displaced from methylated DNA by notch in Xenopus embryos. Mol Cell 2003;12:425-35.
91. Akbarian S, Chen RZ, Gribnau J, Rasmussen TP, Fong H, Jaenisch R, Jones EG. Expression pattern of the Rett syndrome gene MeCP2 in primate prefrontal cortex. Neurobiol Dis 2001;8:784-91.
92. Jung BP, Jugloff DG, Zhang G, Logon R, Brown S, Eubanks JH. The expression of methyl CpG binding factor MeCP2 correlates with cellular differentiation in the developing rat brain and in cultured cells. J Neurobiol 2003;55:86-96.
93. Shahbazian MD, Antalffy B, Armstrong DL, Zoghbi HY. Insight into Rett syndrome: MeCP2 levels display tissue- and cell-specific differences and correlate with neuronal maturation. Hum Mol Genet 2002;11:115-24.
94. Aber KM, Nori P, MacDonald SM, Bibat G, Jarrar MH, Kaufmann WE. Methyl-CpG-binding protein 2 is localized in the postsynaptic compartment: an immunochemical study of subcellular fractions. Neurosci 2003;116:77-80.
95. Chen WG, Chang Q, Lin Y, Meissner A, West AE, Griffith EC, Jaenisch R, Greenberg ME. Derepression of BDNF transcription involves calcium-dependent phosphorylation of MeCP2. Science 2003;302:885-9.
96. Martinowich K, Hattori D, Wu H, Fouse S, He F, Hu Y, Fan G, Sun YE. DNA methylation-related chromatin remodeling in activity-dependent BDNF gene regulation. Science 2003;302:890-3.
97. Scala E, Ariani F, Mari F, Caselli R, Pescucci C, Longo I, Meloni I, Giachino D, Bruttini M, Hayek G, Zapella M, Renieri A. STK9 is mutated in Rett syndrome variant with infantile spasms. J Med Genet (in press).
98. Kalscheuer VM, Tao J, Donnelly A, Hollway G, Schwinger E, Kubart S, Menzel C, Hoeltzenbein M, Tommerup N, Eyre H, Harbard M, Haan E, Sutherland GR, Ropers HH, Gecz J. Disruption of the serine/threonine kinase 9 gene causes severe X-linked infantile spasms and mental retardation. Am J Hum Genet 2003;72:1401-11.
99. Huoponiemi L, Tyynismaa H, Rantala A, Rosenberg T, Alitalo T. Characterization of two unusual RS1 gene deletions segregating in Danish retinoschisis families. Human Mut 2000;16:307-14.
100. Stromme P, Mangelsdorf ME, Scheffer IE, Gecz J. Infantile spasms, dystonia, and other X-linked phenotypes caused by mutations in Aristaless related homeobox gene, ARX. Nat Genet 2002;30:441-5.
101. Montini E, Andolfi G, Caruso A, Buchner G, Walpole SM, Mariani M, Consalez G, Trump D, Ballabio A, Franco B. Identification and characterization of a novel serine-threonine kinase gene from the Xp22 region. Genomics 1998;51:427-33.
102. Brunner B, Todt T, Lenzner S, Stout K, Schulz U, Ropers HH, Kalscheuer VM. Genomic structure and comparative analysis of nine fugu genes: Conservation of synteny witn human chromosome Xp22.2-p22.1. Genome Res 1999;9:437-48.
103. Klose R, Bird A. Molecular biology. MeCP2 repression goes nonglobal. Science 2003;302:793-5.